Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predicting Longitudinal Cognitive Decline in MS Using Baseline Clinical Routine T2-FLAIR MRI
Aging, Dementia, and Behavioral Neurology
P14 - Poster Session 14 (8:00 AM-9:00 AM)
10-004

To predict whether people with multiple sclerosis (PwMS) exhibit longitudinal cognitive decline from baseline clinical MRI data using artificial intelligence and state-of-the-art automated processing methods for measuring atrophy and structural network disruption.

Longitudinal cognitive decline in PwMS can in part be predicted from baseline research-quality MRI and intensive processing pipelines. However, newer techniques are available to automatically generate robust quantitative and network-level data from routine, clinical T2-FLAIR MRI, with minimal user expertise.

A retrospective analysis of 147 PwMS was conducted to predict cognitive decline over several years (mean=3.9±2.2) from baseline clinical T2-FLAIR MRI. The previously validated NeuroSTREAM and Network Modification tools were applied on baseline T2-FLAIR MRI to automatically measure lateral ventricular volume and patterns of structural network white matter tract disruption, respectively. This baseline data was then applied to predict cognitive decline, defined as a drop in 4-points or greater on the Symbol Digit Modalities Test (SDMT). The data was divided randomly into two discrete subsets (n=117; n=30). The first was used to train a modular deep neural network to predict cognitive decline and the other was used to test/validate the predictive accuracy of the model.

44.8% of study participants (n=50 training; n=16 testing) exhibited cognitive decline over the period of observation. After training the modular deep neural network, we achieved moderate predictive accuracy in the separate test/validation set (accuracy=63%; sensitivity=0.65; specificity=0.86; false positive=2; false negative=9; F1=0.62). These results compare favorably to previously reported R2 values of 0.20-0.35 on research-quality full connectomic investigations.

With the application of state-of-the-art automated MRI processing pipelines and artificial intelligence, cognitive decline in PwMS can be predicted from routine, clinical-quality, T2-FLAIR MRI data with minimal user expertise. These automated methods may allow for patient risk-stratification even in clinical environments.
Authors/Disclosures
Tom Fuchs (Buffalo Neuroimaging Analysis Center)
PRESENTER
Mr. Fuchs has nothing to disclose.
Ralph H. Benedict, PhD (University At Buffalo) Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic Therapeutics. Dr. Benedict has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo) Prof. Bergsland has nothing to disclose.
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo) Dr. Jakimovski has nothing to disclose.
No disclosure on file
Robert Zivadinov, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center) Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.